Healthcare Cognitive Screening

Millions of people around the world suffer from mild to severe cognitive impairment. Solutions for screening, diagnosis, and treatment of brain diseases, disorders, and injuries are imperative.

Cogstate delivers innovative solutions to meet these needs through our technology and our partnerships. We provide tools to screen and monitor cognitive changes in the healthcare and community settings that support clinical evaluation and self-assessment of brain health.

Learn More – Talk to Our Team


Explore Cognitive Assessment Solutions

Cognigram | For Healthcare Professionals

Cognigram™ is a simple and scientifically valid computerized test system intended to aid healthcare professionals with rapid assessment of cognition in individuals aged 6 – 99 years old. The system is a HIPAA compliant U.S. FDA Class II Exempt Digital Medical Device, which has received marketing authorization in multiple additional regulatory jurisdictions around the world. The tests are trusted and widely adopted in academic research and pharmaceutical drug trials.

Eisai Partnership | NouKNOW and CogMate

Cogstate and pharmaceutical company Eisai Co. Ltd established a global partnership to develop and commercialize digital brain performance assessment tools for individuals and doctors. The first product launched under this collaboration is “NouKNOW®,” available in Japan, followed by the multilingual version called “CogMate™”. Both products are self-assessments of brain performance based on the Cogstate cognitive tests.

The Reality of Cognitive Impairment


1 in 10 people aged 65 years or older has Alzheimer’s disease.

The Cognigram system detects very subtle changes in cognition that could signify the early stages of dementia. Because neurological changes begin 20 or more years before cognitive symptoms appear, early detection of dementia is critical.


Post-surgical delirium affects up to 50% of patients, costing $164 billion per year.

In the perioperative setting, postoperative cognitive dysfunction (POCD) occurs in up to 53% of patients over 65 years of age and in patients with moderate to severe cases, decline in cognitive function can be substantial and long term.


42 million people globally suffer from concussion each year.

The Cognigram system offers unique value as a sensitive and reliable tool for baseline testing and post-injury evaluation. Sport organizations ranging from secondary education to professional and elite groups around the world depend upon its test battery for decision support in their concussion management programs.

How can we help you optimize the measurement of brain health?

Contact Our Team